FATE - FATE THERAPEUTICS INC

QQQ $ 445.88 $ 2.85 (0.64 %)

DIA $ 395.58 $ 1.12 (0.28 %)

SPY $ 523.16 $ 2.39 (0.46 %)

TLT $ 90.86 $ 0.51 (0.56 %)

GLD $ 218.12 $ 1.83 (0.85 %)

Previous Close

$ 4.22

Open

$ 4.18

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 4.08 - $ 4.28

52 Week Range

$ 1.63 - $ 8.83

Volume

2,483,361

Average Volume

Market Cap

426.66M

Beta (5Y Monthly)

$ 1.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	02-26-2024	12-31-2023	10-K
3	11-08-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-03-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-03-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-28-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-04-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-24-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-11-2020	03-31-2020	10-Q
18	03-02-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	03-05-2019	12-31-2018	10-K
23	11-01-2018	09-30-2018	10-Q
24	08-06-2018	06-30-2018	10-Q
25	05-10-2018	03-31-2018	10-Q
26	03-05-2018	12-31-2017	10-K
27	11-01-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-15-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-08-2016	06-30-2016	10-Q
33	05-09-2016	03-31-2016	10-Q
34	03-03-2016	12-31-2015	10-K
35	11-03-2015	09-30-2015	10-Q
36	08-05-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	03-12-2015	12-31-2014	10-K
39	11-12-2014	09-30-2014	10-Q
40	08-12-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Canaccord Genuity Maintains Buy on Fate Th...
05/10/2024 18:37:42

Canaccord Genuity analyst Bill Maughan maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and lowers the price target from...

BMO Capital Maintains Market Perform on Fa...
05/10/2024 15:16:19

BMO Capital analyst Etzer Darout maintains Fate Therapeutics (NASDAQ:FATE) with a Market Perform and lowers the price target...

Wedbush Maintains Neutral on Fate Therapeu...
05/10/2024 13:38:07

Wedbush analyst David Nierengarten maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from...

Piper Sandler Maintains Neutral on Fate Th...
05/10/2024 13:18:21

Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target f...

Fate Therapeutics Q1 2024 GAAP EPS $(0.47)...
05/09/2024 20:05:49

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This i...

Fate Therapeutics Treats First Lupus Patie...
05/09/2024 12:33:33

Forecasting The Future: 8 Analyst Projecti...
05/06/2024 16:00:41

Wedbush Reiterates Neutral on Fate Therape...
05/06/2024 12:23:57

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

Fate Therapeutics Announces Presentation O...
05/03/2024 20:31:26

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Techn...

Wedbush Reiterates Neutral on Fate Therape...
04/23/2024 17:12:50

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

Fate Therapeutics To Present FT819 Proof-O...
04/22/2024 20:35:00

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Im...

Where Fate Therapeutics Stands With Analysts
04/11/2024 14:00:17

Needham Reiterates Hold on Fate Therapeutics
04/11/2024 10:09:37

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

B of A Securities Maintains Underperform o...
03/28/2024 18:13:21

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ:FATE) with a Underperform and raises the price ta...

Fate Therapeutics Announces Pricing Of $10...
03/19/2024 12:45:53

Evaluating Fate Therapeutics: Insights Fro...
03/19/2024 12:00:21

HC Wainwright & Co. Reiterates Neutral on ...
03/19/2024 10:53:43

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $...

Cracking The Code: Understanding Analyst R...
02/27/2024 20:00:24

Barclays Maintains Overweight on Fate Ther...
02/27/2024 14:37:02

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $...